Dan Ollendorf News Today

Pharmaceutical companies last year launched new US drugs at prices 35 per cent higher than in 2022, reflecting in part the industry's embrace of expensive therapies for rare diseases like muscular dystrophy, a Reuters analysis found. The median annual list price for a new drug was US$300,000 (S$402,900) in 2023, according to the Reuters analysis of 47 medicines, up from...

Reuters analysed 55 novel drugs approved by the FDA last year, up from 37 in 2022

Pharmaceutical companies last year launched new U.S. drugs at prices 35% higher than in 2022, reflecting in part the industrys embrace of expensive therapies for rare diseases like muscular dystrophy, a Reuters analysis found.

Pharmaceutical companies last year launched new U.S. drugs at prices 35% higher than in 2022, reflecting in part the industry's embrace of expensive therapies for rare diseases like muscular dystrophy, a Reuters analysis found. The median annual list price for a new drug was $300,000 in 2023, according to the Reuters analysis of 47 medicines, up from $222,000 a year earlier. In 2021, the median annual price was $180,000 for the 30 drugs first marketed through mid-July, according to a stud...

Pharmaceutical companies last year launched new U.S. drugs at prices 35% higher than in 2022, reflecting in part the industry's embrace of expensive therapies for rare...

Pharmaceutical companies last year launched new U.S. drugs at prices 35% higher than in 2022, reflecting in part the industrys embrace of expensive therapies for rare diseases like muscular...

By Deena Beasley (Reuters) - Pharmaceutical companies last year launched new U.S. drugs at prices 35% higher than in 2022, reflecting in part the ...

/PRNewswire/ -- Gilde Healthcare, the specialized healthcare investor with €2 billion raised in dedicated sector funds, today announced the establishment of...